Advertisement
Research ArticleArticle

Combined Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Cytochrome P450 2B6 Substrates and Protein Homology Modeling

Qinmi Wang and James R. Halpert
Drug Metabolism and Disposition January 2002, 30 (1) 86-95; DOI: https://doi.org/10.1124/dmd.30.1.86

Abstract

Understanding the basis of the substrate specificity of cytochrome P450 2B6 (CYP2B6) is important for determining the role of this enzyme in drug metabolism and for predicting new substrates. Pharmacophores were generated for 16 structurally diverse CYP2B6 substrates with Catalyst after overlapping the reaction sites. Two pharmacophores were determined for the CYP2B6 binding site. Both include two hydrophobes and one hydrogen bond acceptor. The three-dimensional structure of CYP2B6 was then modeled based on the crystal structure of CYP2C5. Benzyloxyresorufin and 7-ethoxy-4-trifluoromethylcoumarin, the two lowestKm substrates in the training set, were then docked in the active site of CYP2B6. The pharmacophores were combined with the CYP2B6 model by comparing the docking results and the mapping of the two substrates with the pharmacophores. The results indicated that the active site of CYP2B6 complements the pharmacophores. The pharmacophores and the CYP2B6 model were used in conjunction to predict the Km values of substrates in a test set of five compounds and yielded satisfactory predictions for benzphetamine, cinnarizine, bupropion, and verapamil but not lidocaine. The CYP2B6 model, the pharmacophores, and the combination of the model with these pharmacophores provide insight into the interactions of CYP2B6 with substrates. The pharmacophores may be used as queries to search a database to predict new substrates for CYP2B6 when the reaction site is known (N- orO-dealkylation). For C-hydroxylation, the CYP2B6 model is helpful in evaluating the possible reaction sites in order for the pharmacophores to predict correspondingKm values.

The cytochromes P450 (P450) are a superfamily of hemoproteins that are involved in oxidative, peroxidative, and reductive metabolic biotransformation of a wide variety of endogenous compounds, such as steroids, prostaglandins, and fatty acids, and exogenous compounds, such as drugs and carcinogens (Ortiz de Montellano, 1995; Nelson et al., 1996). Individual P450s exhibit unique substrate specificity and regio- and stereoselectivity profiles that reflect different tertiary structures. The CYP2B subfamily contains some of the first P450s to be cloned and purified and has served as a model system for mammalian P450 structure-function analysis through the use of allelic variants, site-directed mutagenesis, and computer-aided molecular modeling (Lewis et al., 1999; Domanski and Halpert, 2001). The CYP2B1 substrate recognition site residues 103, 114, 115, 206, 209, 290, 294, 297, 298, 302, 362, 363, 367, 477, 478, and 480 have been demonstrated to be very important for substrate metabolism (Domanski and Halpert, 2001;Domanski et al., 2001). Human CYP2B6 metabolizes about 3% of drugs in clinical use, and structure-function analyses have only recently begun as new clinically relevant substrates have been identified (Rendic and Di Carlo, 1997) and heterologous expression has been accomplished (Hanna et al., 2000). More work is necessary to understand the structure and specificity of CYP2B6 and its role in metabolism.

Recently efforts have intensified to use the quantitative structure-activity relationship (QSAR) for understanding P450 active sites (Ekins et al., 2001). Such approaches are based on the idea of combining chemical knowledge about small compounds with experimental data obtained from in vitro systems. A considerable number of current QSAR models have been generated for P450s, especially for CYP2B6, 2C9, 2D6, and 3A4 (Koymans et al., 1992; Strobl et al., 1993; Jones et al., 1996; Rao et al., 2000; Ekins et al., 1999a,b,c,d, 2000). The QSAR approaches used include comparative molecular-field analysis, Catalyst, and molecular surface-weighted holistic invariant molecular analysis. Comparative molecular-field analysis is dependent on the alignment of small compounds, whereas Catalyst is alignment independent. In some cases, the pharmacophores were combined with homology models of P450s and provide a more powerful tool to investigate the active-site features and substrate interactions (de Groot et al., 1999a,b; Afzelius et al., 2001). A novel and selective CYP2D6 substrate, which is suitable for high-throughput screening, has already been successfully designed with the help of one of these models (Onderwater et al., 1999).

Two 3D-QSAR models were generated for CYP2B6 substrates (Ekins et al., 1999c). One is a pharmacophore model built by Catalyst and consisting of three hydrophobes and one hydrogen bond acceptor region. The other partial least-squares model was generated using molecular surface-weighted holistic invariant molecular descriptors. Molecular size, positive electrostatic potential, hydrogen bond acceptors, and hydrophobicity were found to be important for CYP2B6 substrate binding. Although both 3D-QSAR models predicted satisfactoryKm values for the majority of the test set molecules, the pharmacophore generated by Catalyst does not overlay the oxidation site of the substrates in the training set. This may be a real limitation for a pharmacophore made for substrates rather than inhibitors.

Only one mammalian P450 (rabbit CYP2C5) has been crystallized to date (Williams et al., 2000). This is a revolution in the study of the structures of these membrane-bound enzymes, but generation of further structures is impeded by the difficulty in obtaining diffraction quality crystals. In the absence of experimental data, homology modeling becomes an important tool to predict the three-dimensional structures of P450 enzymes. Several reviews have recently addressed the homology modeling of P450s (de Groot and Vermeulen, 1997; Szklarz and Halpert, 1997a; Peterson and Graham, 1998). Early models were based on one or more of four bacterial crystal structures (Szklarz and Halpert, 1997b). However, recently models have been built based on CYP2C5 structures, including CYP2B1, 2B4, and 2B5 (Spatzenegger et al., 2001) and CYP2C9 (Afzelius et al., 2001). These homology models provide a structural basis for understanding the mechanism of P450-mediated drug metabolism and drug-drug interactions.

In this study, we used Catalyst to generate pharmacophores for CYP2B6 substrates with the reaction site of each substrate overlaid. In addition, a model of CYP2B6 was constructed by homology modeling based on the crystal structure of CYP2C5. The pharmacophores were combined with the CYP2B6 model by docking the substrates in the active site of CYP2B6. Finally, the pharmacophores were used to predict theKm value for test set molecules in conjunction with the CYP2B6 model. The combined model holds increased potential to study and predict CYP2B6-mediated drug metabolism.

Materials and Methods

Pharmacophore Generation for CYP2B6 Substrates.

Pharmacophore generation was done using Catalyst (Molecular Simulations, Inc., San Diego, CA). The structures of CYP2B6 substrates were built interactively using the View Compounds Workbench. The conformational search was performed on each structure using the best conformer generation method in Catalyst. The number of conformers for each substrate was limited to a maximum of 250 with an energy range of 20 kcal/mol. The three-dimensional pharmacophore models were generated based on the Km values and the conformers of the substrates by selecting the default chemical functions in the Feature Dictionary in Catalyst, including hydrogen bond donor or acceptor, hydrophobic, negative or positive ionizable features, etc. The substrates were then fit to the generated pharmacophore models. The results showed that the sites of oxidation of the substrates were not overlaid when they were fit to the pharmacophore models because there is no default function in the Feature Dictionary that can recognize the reaction sites of the substrates and then overlay them together when a pharmacophore is generated.

To force overlay of the reaction sites, a novel function was created to include the structural features of the reaction site for each substrate. The new function was then saved in the Feature Dictionary of Catalyst. For example, for compounds that undergoN-demethylation (Fig. 1), the common N-CH3 group for each substrate was put in the novel function in the Feature Dictionary. Catalyst thus can recognize the reaction by searching for the N-CH3group in the structure of a pertinent compound. ForO-deethylation substrates, the common O-CH2CH3 group was included in the Feature Dictionary. For substrates that undergo C-hydroxylation, the specific substructure, including the reaction site was included in the Feature Dictionary in order for Catalyst to recognize the reaction site. The pharmacophore models were again generated by selecting the hydrogen bond donor, hydrogen bond acceptor, hydrophobic groups, and the novel functions in the Feature Dictionary.

Figure 1
Figure 1

The structures of CYP2B6 substrates in the training set and test set.

∗, denotes a chiral carbon.

The pharmacophore models generated were evaluated by cost analysis in Catalyst. The lowest cost hypothesis is considered to be the best. However, hypotheses with costs within 10 to 15 arbitrary units of the lowest cost hypothesis should also be considered good candidates (Catalyst Tutorials; Molecular Simulations, Inc.).

Homology Modeling of CYP2B6.

The three-dimensional structure of human CYP2B6 was built based on the crystal structure of CYP2C5 (Williams et al., 2000) using Insight II/Homology and Insight II/Discover-3 modules (Molecular Simulations, Inc.). The sequence of CYP2B6 was obtained from SwissProt (accession number P20813). The sequence alignment of CYP2B6 and 2C5 was done by GCG (Wisconsin Package Version 10.0; Genetics Computer Group, Madison, WI). The crystal structure of CYP2C5 lacks the N-terminal residues 1 to 29 and F-G loop residues 212 to 222. Correspondingly, the CYP2B6 was modeled from residues 31 to 491. The segment in CYP2B6 corresponding to residues 212 to 222 in CYP2C5 was constructed based on the coordinates of CYP2C5 containing one of two alternative models for density corresponding to the F-G loop (E. F. Johnson, unpublished observation). For residues 276 to 278, the only segment not considered to be conserved, the coordinates were generated by searching the PDB databank to find the regions of proteins that meet the geometric criteria of the loop. The coordinates of the other residues were assigned based on CYP2C5. The heme group was copied from CYP2C5 into the CYP2B6 model.

This preliminary structure was then subjected to molecular mechanics (MM) energy refinement by the Insight II/Discover-3 module with conjugate gradients to a maximum of 1 kcal mol−1Å−1. The parameters for the heme group were described previously (Paulsen and Ornstein, 1991, 1992). The default cvff force field of Insight II was used for the rest of the model. First, the splices between residues 275 and 276, 278 and 279 were repaired to avoid steric hindrance in these junction regions. The loop of residues 276 to 278 was relaxed using molecular dynamics followed by MM minimization. All the hydrogen atoms were put into minimization while the remaining heavy atoms were fixed. The side chains were minimized with the backbone atoms fixed. A 25-Å sphere and a 3-Å surface layer of water were soaked into and around the CYP2B6 structure to provide a solution environment. Finally, MM energy minimization was performed again on the whole soaked enzyme followed by a 150-ps molecular dynamics calculation with the soaked waters fixed.

The CYP2B6 model was analyzed by Prostat in the Insight II/Homology module. The cutoff used, which represents the significant difference for bond length, bond angle, and torsion from the reference value, is 5 S.D. No bond distances, seven bond angles, and 10 dihedral angles were identified to have more than 5 S.D.

Docking.

Benzyloxyresorufin and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) were docked automatically in the active site of the CYP2B6 model using the Insight II/Affinity module. The conformer of each docked substrate that fits the pharmacophore the best was exported from Catalyst to be the initial structure for docking.

Pharmacophore Validation by a Test Set of Substrates.

A series of substrates in the test set were used to validate the pharmacophore models. A conformational search was also performed on the test set substrates. Each substrate was mapped to the pharmacophore by the Best Fit Compare method in Catalyst. All conformers of the substrate were checked during the mapping process. Therefore, a number of mappings to the pharmacophore were obtained for each substrate. The predicted activity, which indicates how active the molecule is estimated to be and how well the molecule matches to the pharmacophore, was estimated for each mapping of the substrate. The mapping in which the substrate is located in the orientation for metabolism was selected with the help of the CYP2B6 model. In this manner, the final predictedKm for each substrate was determined.

Results

Pharmacophores of CYP2B6 Substrates.

Pharmacophore models were generated for a training set of 16 structurally diverse substrates of CYP2B6 (Fig. 1) withKm values shown in Table1. The Kmvalues were obtained from the literature and were generated with CYP2B6 expressed in β-lymphoblastoid cells. Eight hypotheses (Table2) were generated by Catalyst. All the hypotheses consist of two hydrophobes and one hydrogen bond acceptor, which are located in different relative positions in each instance.

View this table:
Table 1

Training set substrates

View this table:
Table 2

Hypotheses generated for CYP2B6 substrates in the training set

Cluster analysis on the eight hypotheses showed that they can be divided into two groups (Table 2). According to the criteria of Catalyst, the lowest cost hypothesis is the best one, although hypotheses within 10 to 15 arbitrary units of the lowest cost should be considered good candidates. Therefore, the lowest cost hypothesis was selected to be the representative pharmacophore in each group. They are hypothesis 1 representing the first group and hypothesis 2 representing the second group (Table 2).

Catalyst tries to map all functions in a hypothesis to one of the two most active training set molecules. Benzyloxyresorufin and 7-EFC are the two lowest Km substrates in the training set (Table 1). Their structures differ significantly (Fig. 1). The molecular size of benzyloxyresorufin is larger than that of 7-EFC. Therefore, Catalyst generated two kinds of pharmacophores primarily based on the different structures of the two lowestKm substrates.

The estimated Km values of benzyloxyresorufin and 7-EFC were predicted by hypotheses 1 and 2, respectively. The experimental Km value (1.3 μM) of benzyloxyresorufin is consistent with its estimatedKm value by hypothesis 1 (2.0 μM) but not by hypothesis 2 (34 μM). The experimentalKm value (1.7 μM) of 7-EFC agrees with the estimated Km value predicted by hypothesis 2 (1.3 μM) but not by hypothesis 1 (48 μM). These results suggested that the correlation coefficient of hypothesis 1 would be increased if 7-EFC were excluded from the training set substrates. Pharmacophores were regenerated for the remaining 15 substrates in the training set. Two hypotheses were generated (Table2B), also including two hydrophobes and one hydrogen bond acceptor. The relative positions of these features are very similar to the two hypotheses in the first group above (Table 2A, hypotheses 1 and 3), but the correlation coefficient for the lowest cost hypothesis is 0.84 rather than 0.76. Similarly, benzyloxyresorufin was excluded from the training substrates to increase the correlation coefficient of hypothesis 2, and pharmacophores were re-generated for the remaining 15 substrates in the training set. Six hypotheses were generated (Table2B) in which the functions have the same relative positions and are very similar to those of the second group hypotheses (Table 2A). The correlation coefficient of the lowest cost hypothesis is 0.82 instead of 0.75 before excluding benzyloxyresorufin. The two kinds of pharmacophore models with correlation coefficients 0.84 and 0.82 (Table2B) are shown as pharmacophore A and B in Fig.2. Both of the pharmacophores include two hydrophobes and one hydrogen bond acceptor located in different relative positions.

Figure 2
Figure 2

Pharmacophores A and B for CYP2B6 substrates.

The R regions (orange) represent the overlaid reaction sites of the substrates. The cyan regions H1, H2, H3, H4 are hydrophobes. The green regions HBA1 and HBA2 stand for hydrogen bond acceptors with the vectors in the directions of the putative hydrogen bond. ∠H1RH2 = 88.6°; ∠H1RHBA1 = 46.1°; ∠H2RHBA1 = 56.8°; ∠H3RH4 = 19.9°; ∠H3RHBA2 = 43.4°; ∠H4RHBA2 = 36.3°.

Benzyloxyresorufin was mapped to pharmacophore A, and 7-EFC was mapped to pharmacophore B (Fig. 3). In Fig. 3A, the two phenyl rings of benzyloxyresorufin fit to the hydrophobic features H1 and H2. It can be inferred that the two phenyl rings may form hydrophobic interactions with the enzyme. The oxygen atom on one of the rings of benzyloxyresorufin matches the hydrogen bond acceptor HBA1 (Fig. 3A). This oxygen atom may accept a hydrogen atom and form a hydrogen bond with the enzyme or a water molecule in the active site. All functions in the pharmacophore B were fit by 7-EFC (Fig. 3B). One of the rings fits the hydrophobic function H3, and the trifluoromethyl group fits another hydrophobic function H4. Both of them may also form hydrophobic interactions with the enzyme. The oxygen atom on the ring fits the hydrogen bond acceptor HBA2 and may form a hydrogen bond with CYP2B6 or a water molecule in the active site.

Figure 3
Figure 3

A, mapping of benzyloxyresorufin with pharmacophore A; B, mapping of 7-EFC with pharmacophore B.

Homology Modeling.

To determine how well the pharmacophores fit the active site of CYP2B6, a three-dimensional structure of human CYP2B6 was built based on the crystal structure of CYP2C5. The sequence alignment is shown in Fig.4. The amino acid residues that have been determined previously to be important for substrate metabolism in the CYP2B subfamily (Domanski and Halpert, 2001; Domanski et al., 2001) are shown in Fig. 5.

Figure 4
Figure 4

Sequence alignment between CYP2B6 and 2C5 from residue 31 to 491.

The GAP method in GCG (Genetics Computer Group) was used for sequence alignment. The sequence identity between CYP2B6 and CYP2C5 is 49%, and the similarity is 61%.

Figure 5
Figure 5

Active site of a CYP2B6 homology model constructed based on the crystal structure of CYP2C5.

The heme group is shown in red. Part of the backbone in the active site is shown as gray ribbons. The substrate recognition site residues determined to be important for substrate metabolism in CYP2B1 are shown in purple.

Combination of the Pharmacophores and the CYP2B6 Model by Docking.

The pharmacophores of the substrates should help one to infer complementary structural features of the CYP2B6 active site. To gain confidence in the pharmacophores, we assessed how well the pharmacophores fit the active site by automatic docking of benzyloxyresorufin and 7-EFC into CYP2B6. The docking results are shown in Figs. 6 and7. The substrates are oriented with the metabolic site pointing to the heme.

Figure 6
Figure 6

Benzyloxyresorufin docked in the active site of CYP2B6.

The heme group is shown in red. Benzyloxyresorufin is shown in orange, and residues within 5 Å are shown in green. The reaction site R and hydrophobes H1 and H2 of pharmacophore A are located according to the orientation and position of benzyloxyresorufin in the active site when compared with the mapping in Fig. 3A. The distance between H1 (the center of the phenyl ring matching H1) and R is 3.9 Å, and the angle ∠H1RH2 equals 90.3°. The values are very similar to the corresponding distance (4.0 Å) and angle (88.6°) in pharmacophore A (Fig. 2A). The distance between R and H2does not vary.

Figure 7
Figure 7

7-EFC docked in the active site of CYP2B6.

Two possible orientations were found for 7-EFC (orange) due to its small molecular size. The enzyme is oriented in the same direction in the two pictures. The heme group is shown in red, and the residues within 5 Å of 7-EFC are shown in green. The reaction site R and hydrophobes H3 and H4 of pharmacophore B are located in the active site according to the orientations and positions of 7-EFC when compared with the mapping in Fig. 3B. The structure of 7-EFC is rigid, requiring that R, H3, and H4are located in almost the same relative position as in pharmacophore B.

The mapping results of benzyloxyresorufin with pharmacophore A (Fig. 3A) and 7-EFC with pharmacophore B (Fig. 3B) were compared with the docking results of the two compounds in the active site of CYP2B6 (Figs. 6 and 7, A and B). Comparison of the positions of benzyloxyresorufin in both Figs. 3A and 6 allowed identification of the reaction site region R, the two hydrophobes H1and H2, and the hydrogen bond acceptor HBA1 of pharmacophore A in the active site of the CYP2B6 model (Fig. 6). No hydrogen bond was identified between benzyloxyresorufin and CYP2B6 from the docking results, suggesting that a water molecule located near the hydrogen bond acceptor may form a hydrogen bond with benzyloxyresorufin. The distances and angles among H1, H2, and R located in the active site of CYP2B6 are very similar to those of pharmacophore A. Thus, pharmacophore A complements the active site of the CYP2B6 model very well.

Docking of 7-EFC (Fig. 7, A and B) indicated that there are two possible orientations for 7-EFC in the active site of CYP2B6. As with benzyloxyresorufin, no hydrogen bond was found between 7-EFC and CYP2B6. From the location of 7-EFC in the active site and the mapping with pharmacophore B (Fig. 3B), the reaction site R and the hydrophobes H3 and H4 of pharmacophore B can be located in CYP2B6, as shown in Fig. 7A and B. The distances and angles among H3, H4, and R in pharmacophore B are very similar to those in the active site. This indicates that pharmacophore B also complements the active site of CYP2B6 very well.

The residues within 5Å of the center of the phenyl ring matching H1 in Fig. 6 are 114, 115, 206, 298, 363, 367, and 477. The residues within 5Å of the center of the ring matching H2 are 206, 297, 298, 301, 302, 363, 477, and 478. With the exception of residue 301, which has not been tested, all of these residues are consistent with experimental results of site-directed mutagenesis of CYP2B1 in Fig. 5 (Domanski and Halpert, 2001).

For the first orientation of 7-EFC (Fig. 7A), residues 206, 298, 302, 363, 367, 477, and 478 are within 5Å of the center of the phenyl ring matching H3, and residues 301, 302, 305, 306, 362, 363, 477, and 479 are within 5Å of the trifluoromethyl group matching H4. For the second orientation of 7-EFC (Fig. 7B), the residues within 5Å of the center of the ring matching H3 are 114, 206, 297, 298, 302, 367, and 477. The residues within 5Å of the trifluoromethyl group matching H4 are 100, 103, 114, 115, 297, and 367. Most of these residues also show excellent agreement with previous CYP2B1 mutagenesis experiments in Fig. 5 (Domanski and Halpert, 2001).

Predictions of the Pharmacophores in Conjunction with the CYP2B6 Model.

The significance of a pharmacophore is determined by its ability to predict new compounds. Pharmacophores A and B were used to predict theKm values for substrates in the test set (Table 3) in conjunction with the CYP2B6 model. The conformers were calculated for each substrate in the test set. A number of mappings were obtained when each substrate was fit to the pharmacophore by Catalyst because each substrate has a number of conformers. Knowing the orientations and positions of pharmacophores in the active site of CYP2B6 helps to select which mapping is the one most suitable for metabolism by CYP2B6. Table 3 gives the experimental and predicted Km values for the test set molecules. Of the total substrates in the test set, theKm values for most were successfully predicted with at least one of the two pharmacophores. It should be noted that the Km values reported for bupropion and verapamil refer to the racemic mixtures. Since theR- and S-enantiomers may bind differently to the enzyme, Km values were predicted for both forms. For both enantiomers of bupropion, pharmacophores A and B give satisfactory predicted Km values, indicating that bupropion may have more than one binding position in the active site of CYP2B6. For verapamil, the predictedKm values are close to the experimental data except for R-verapamil and pharmacophore B. An exception to the predictive power of the pharmacophores is lidocaine. There are two ethyl groups attached to the N atom (Fig. 1). Although lidocaine fits pharmacophores A and B very well (the predictedKm is low; Table 3), the two ethyl groups may hinder the access of the N atom to the heme iron. This may explain why the predicted Km is lower than the experimental Km (Table 3).

View this table:
Table 3

Test set substrates

Discussion

Two pharmacophores were determined for CYP2B6 substrates in this study, both of which include two hydrophobic regions and one hydrogen bond acceptor. The correlation coefficients of the two pharmacophores are 0.84 and 0.82. Both pharmacophores complement the active site of a CYP2B6 homology model based on CYP2C5 and gave satisfactory estimatedKm values for the majority of the test set molecules in conjunction with the protein model. Pharmacophore A is located in one part of the active site, and pharmacophore B is located in another position, with some overlap between the two pharmacophores, indicating that different possible binding locations exist within the active site of the enzyme. The results are consistent with previous QSAR studies on CYP2B proteins that suggested the importance of hydrophobic and electronic properties in the binding of substrates (Lewis et al., 1999; Ekins et al., 1999c).

Initially, we sought to investigate the active-site features of CYP2B6 by combining our new three-dimensional homology model with the existing substrate pharmacophore of CYP2B6 generated by Catalyst (Ekins et al., 1999c). Following the procedures in that study we recreated the pharmacophore, which gave satisfactory predictedKm values for the majority of the test set molecules (data not shown). However, we realized that the oxidation sites of the substrates in the training set had not been overlaid when they were mapped to the pharmacophore. Since the site of oxidation of the substrates should point toward the heme iron in the enzyme, a new function was made and saved in the Feature Dictionary in Catalyst to force the reaction site of each substrate to be overlaid when the pharmacophores were generated.

In constructing the new pharmacophores, we made some modifications to the initial training set of 16 compounds. In particular, antipyrine was deleted due to questions about the validity of the very highKm value (17.7 mM). In addition, benzphetamine and cinnarizine were moved to the test set (Table 1). These three compounds were replaced in the training set by arteether, amitriptyline, and propofol. Five compounds with different metabolic pathways are thus included in the test set (Table 3) in this study to assess pharmacophore A and B. In addition, the R- andS-enantiomers of bupropion and verapamil in the test set were considered. The reported Km values of the two compounds correspond to the racemic mixtures. However, theR- and S-forms differ in their binding with the CYP2B6 model. Therefore, the Km values were predicted for both R- and S-enantiomers of the two compounds. Consideration of the stereochemistry had relatively little impact with bupropion or with pharmacophore A and verapamil. However, pharmacophore B predicted a Km in the millimolar range for R-verapamil. In the article byEkins et al. (1999c), the R- and S-forms were not distinguished when the Km values were predicted for bupropion and verapamil.

The pharmacophore model made by Ekins consists of three hydrophobes and one hydrogen bond acceptor region. The pharmacophores generated in this study include two instead of three hydrophobes, one hydrogen bond acceptor, and an additional reaction site. If the mapping of 7-EFC with the pharmacophore in the article by Ekins et al. (1999c) is compared with that (Fig. 3B) in this study, we can see that the phenyl ring to which the ethoxy group attaches matches a hydrophobe in both studies. The trifluoromethyl group attached to position 4 of the other ring also fits a second hydrophobe in both studies. Therefore, the hydrophobicity of the trifluoromethyl group and the phenyl ring may be very important for 7-EFC binding. If the structures of 7-ethoxy-4-trifluoromethylcoumarin, 4-chloromethyl-7-ethoxycoumarin, and 7-ethoxycoumarin (Fig. 1) are compared, only the first two compounds have a group in position 4 of the phenyl ring, and theirKm values (1.7 and 33.7 μM; Table 1) are lower than that of the third compound (115 μM; Table 1). This suggests that 4-substituent contributes to substrate binding in the active site of CYP2B6.

Lewis et al. (1999) constructed a three-dimensional homology model of CYP2B6 based on bacterial CYP102. A series of substrates were docked into the active site of the constructed model. The substrate template was then obtained by superimposing the docked substrates. Although the template yielded some important features for the substrates, the low sequence similarity between CYP2B6 and CYP102 is a major drawback. In our study, we had the advantage of having a closely related mammalian CYP2C5 crystal structure to construct the homology model CYP2B6. The higher sequence identity and similarity between the CYP2C5 and CYP2B6 make the constructed model more reliable.

Several recent studies have focused on the combination of pharmacophores of small compounds and homology models of P450 enzymes.Afzelius et al. (2001) generated a 3D-QSAR model for 29 structurally diverse competitive CYP2C9 inhibitors. The 3D-QSAR model was constructed with the help of the homology model of CYP2C9. The CYP2C9 inhibitors were docked into the active site of the homology model, and then the active conformers of the inhibitors were selected and used in the 3D-QSAR analysis. The 3D-QSAR model was able to predict the entire test set molecules within 0.5 log units of the experimentalKi values. The active site residues of the homology model of CYP2C9 complement the features of the 3D-QSAR model. Furthermore, de Groot et al. (1999a,b) have also published a combined protein and pharmacophore model for CYP2D6. The pharmacophore model was constructed by overlaying 40 substrates using some distance criteria. Then the derived pharmacophore model was oriented into the active site of the CYP2D6 homology model. The pharmacophore model complemented the protein model perfectly, although the two models were derived independently, thereby validating each other. Normally, pharmacophore or 3D-QSAR models are used to study substrate/inhibitor binding site features and design new compounds without knowledge of the target protein structure. However, if pharmacophore or 3D-QSAR models are combined with three-dimensional structures of proteins, the reliability and the predictive power of the model should be enhanced. In this study, the two pharmacophores were also combined with the CYP2B6 model to deduce the orientations and positions of the pharmacophores in the active site of the enzyme. In the future, the pharmacophores, in conjunction with the protein model, may be used as queries to search a database to predict substrates for CYP2B6. For a compound in which the reaction site is known (N- or O-dealkylation), the two pharmacophores, along with knowledge of their orientations and positions in the active site, can be used directly to predictKm values and evaluate the possibility of metabolism by CYP2B6. For compounds that undergoC-hydroxylation, the reaction sites could be multiple. The homology model can also be used to predict the reaction site by docking the compound into the active site. Then theKm values can be predicted based on the knowledge of the orientations and positions of the pharmacophores in the active site.

Acknowledgments

We thank Drs. James M. Briggs and Gillian C. Lynch at the University of Houston (Houston, TX) for helpful suggestions. We also acknowledge Drs. Emily E. Scott and Tammy L. Domanski for help with the manuscript.

Footnotes

  • Supported by AstraZeneca and National Institutes of Health Grant ES03619 (J.R.H.) and Center Grant ES06676.

  • Abbreviations used are::
    P450
    cytochrome P450
    3D-QSAR
    three-dimensional quantitative structure-activity relationship
    MM
    molecular mechanics
    7-EFC
    7-ethoxy-4-trifluoromethylcoumarin
    HBA
    hydrogen bond acceptor
    • Received July 24, 2001.
    • Accepted October 4, 2001.

References

  1. ↵
    1. Afzelius L,
    2. Zamora I,
    3. Ridderstrom M,
    4. Andersson TB,
    5. Karlen A,
    6. Masimirembwa CM
    (2001) Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol 59:909–919.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Court MH,
    2. Duan SX,
    3. Hesse LM,
    4. Venkatakrishnan K,
    5. Greenblatt D
    (2001) Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94:110–119.
    OpenUrlCrossRefPubMed
  3. ↵
    1. de Groot MJ,
    2. Ackland MJ,
    3. Horne VA,
    4. Alex AA,
    5. Jones BC
    (1999a) Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. J Med Chem 42:1515–1524.
    OpenUrlCrossRefPubMed
  4. ↵
    1. de Groot MJ,
    2. Ackland MJ,
    3. Horne VA,
    4. Alex AA,
    5. Jones BC
    (1999b) A novel approach to predicting P450-mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J Med Chem 42:4062–4070.
    OpenUrlCrossRefPubMed
  5. ↵
    1. de Groot MJ,
    2. Vermeulen NP
    (1997) Modeling the active sites of cytochrome P450s and glutathione S-transferases, two of the most important biotransformation enzymes. Drug Metab Rev 29:747–799.
    OpenUrlPubMed
  6. ↵
    1. Domanski TL,
    2. Halpert JR
    (2001) Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Metab 2:117–137.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Domanski TL,
    2. He Y-Q,
    3. Scott EE,
    4. Wang Q,
    5. Halpert JR
    (2001) The role of cytochrome 2B1 substrate recognition site residues 115, 294, 297, 298 and 362 in the oxidation of steroids and 7-alkoxycoumarins. Arch Biochem Biophys 394:21–28.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ekins S,
    2. Bravi G,
    3. Binkley S,
    4. Gillespie JS,
    5. Ring BJ,
    6. Wikel JH,
    7. Wrighton SA
    (1999a) Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 9:477–489.
    OpenUrlPubMed
  9. ↵
    1. Ekins S,
    2. Bravi G,
    3. Binkley S,
    4. Gillespie JS,
    5. Ring BJ,
    6. Wikel JH,
    7. Wrighton SA
    (1999b) Three-dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4. J Pharmacol Exp Ther 290:429–438.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Ekins S,
    2. Bravi G,
    3. Binkley S,
    4. Gillespie JS,
    5. Ring B,
    6. Wikel J,
    7. Wrighton SA
    (2000) Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 28:994–1002.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Ekins S,
    2. Bravi G,
    3. Ring BJ,
    4. Gillespie TA,
    5. Gillespie JS,
    6. VandenBranden M,
    7. Wrighton SA,
    8. Wikel JH
    (1999c) Three-dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6. J Pharmacol Exp Ther 288:21–29.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Ekins S,
    2. Bravi G,
    3. Wikel JH,
    4. Wrighton SA
    (1999d) Three-dimensional quantitative structure activity relationship (3D-QSAR) analysis of CYP3A4 substrates. J Pharmacol Exp Ther 291:424–433.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Ekins S,
    2. de Groot MJ,
    3. Jones JP
    (2001) Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 29:936–944.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Ekins S,
    2. Vandenbranden M,
    3. Ring BJ,
    4. Gillespie JS,
    5. Yang TJ,
    6. Gelboin HV,
    7. Wrighton SA
    (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253–1259.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Ekins S,
    2. VandenBranden M,
    3. Ring BJ,
    4. Wrighton SA
    (1997) Examination of purported probes of human CYP2B6. Pharmacogenetics 7:165–179.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Grace JM,
    2. Aguilar AJ,
    3. Trotman KM,
    4. Brewer TG
    (1998) Metabolism of B-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab Dispos 26:313–317.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Hanna IH,
    2. Reed JR,
    3. Guengerich FP,
    4. Hollenberg PF
    (2000) Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. Arch Biochem Biophys 376:206–216.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Heyn H,
    2. White RB,
    3. Stevens JC
    (1996) Catalytic role of cytochrome P250 2B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948–954.
    OpenUrlAbstract
  19. ↵
    1. Jones JP,
    2. He M,
    3. Trager WF,
    4. Rettie AE
    (1996) Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P450 2C9. Drug Metab Dispos 24:1–6.
    OpenUrlPubMed
  20. ↵
    1. Kariya S,
    2. Isozaki S,
    3. Uchino K,
    4. Suzuki T,
    5. Narimatsu S
    (1996) Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull 19:1511–1514.
    OpenUrlPubMed
  21. ↵
    1. Koyama E,
    2. Chiba K,
    3. Tani M,
    4. Ishizaki T
    (1997) Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 281:1199–1210.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Koymans L,
    2. Vermeulen NP,
    3. van Acker SA,
    4. te Koppele JM,
    5. Heykats JJ,
    6. Lavrijsen K,
    7. Meuldermans W,
    8. Donne-Op den Kelder GM
    (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211–219.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Lewis DF,
    2. Lake BD,
    3. Dickins M,
    4. Eddershaw PJ,
    5. Tarbit MH,
    6. Goldfarb PS
    (1999) Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. Xenobiotica 29:361–393.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Nelson DR,
    2. Koymans L,
    3. Kamataki T,
    4. Stegeman JJ,
    5. Feyereisen R,
    6. Waxman DJ,
    7. Waterman MR,
    8. Gotoh O,
    9. Coon MJ,
    10. Estabrook RW,
    11. et al.
    (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1–42.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Onderwater RC,
    2. Venhorst J,
    3. Commandeur JNM,
    4. Vermeulen NPE
    (1999) Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening. Chem Res Toxicol 12:555–559.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ono S,
    2. Hatanaka T,
    3. Miyazawa S,
    4. Tsutsui M,
    5. Aoyama T,
    6. Gonzalez FJ,
    7. Satoh T
    (1996) Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19, and the 3A subfamily. Xenobiotica 26:1155–1166.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Ortiz de Montellano P
    (1995) Cytochrome P450 Structure, Mechanism, and Biochemistry (Plenum Press, New York).
  28. ↵
    1. Paulsen MD,
    2. Ornstein RL
    (1991) A 175-psec molecular dynamics simulation of camphor-bound cytochrome P-450cam. Proteins 11:184–204.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Paulsen MD,
    2. Ornstein RL
    (1992) Predicting the product specificity and coupling of cytochrome P450cam. J Comp-Aided Mol Des 6:235–252.
    OpenUrl
  30. ↵
    1. Peterson JA,
    2. Graham SE
    (1998) A close family resemblance: the importance of structure in understanding cytochromes P450. Structure 6:1079–1085.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Rao S,
    2. Aoyama R,
    3. Schrag M,
    4. Trager WF,
    5. Rettie A,
    6. Jones PJ
    (2000) A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. J Med Chem 43:2789–2796.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Rendic S,
    2. Di Carlo FJ
    (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413–580.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Spatzenegger M,
    2. Wang Q,
    3. He Y-Q,
    4. Wester MR,
    5. Johnson EF,
    6. Halpert JR
    (2001) Amino acid residues critical for differential inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles. Mol Pharmacol 59:475–485.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Stevens JC,
    2. White RB,
    3. Hsu SH,
    4. Martinet M
    (1997) Human liver CYP2B6-catalyzed hydroxylation of RP73401. J Pharmacol Exp Ther 282:1389–1395.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Strobl GR,
    2. von Kruedener S,
    3. Stockigt J,
    4. Guengerich FP,
    5. Wolff T
    (1993) Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies. J Med Chem 36:1136–1145.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Szklarz GD,
    2. Halpert JR
    (1997a) Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. Life Sci 61:2507–2520.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Szklarz GD,
    2. Halpert JR
    (1997b) Molecular modeling of cytochrome P450 3A4. J Comp-Aided Mol Des 11:265–272.
    OpenUrl
  38. ↵
    1. Williams PA,
    2. Cosme J,
    3. Sridhar V,
    4. Johnson EF,
    5. McRee DE
    (2000) Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 5:121–131.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Wormhoudt LW,
    2. Ploemen JHTM,
    3. de Waziers I,
    4. Commandeur JNM,
    5. Beaune PH,
    6. van Bladeren PJ,
    7. Vermeulen NPE
    (1996) Inter-individual variability in the oxidation of 1,2-dibromoethane: use of heterologously expressed human cytochrome P450 and human liver microsomes. Chem Biol Interact 101:175–192.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Yamazaki H,
    2. Inoue K,
    3. Mimura M,
    4. Oda Y,
    5. Guengerich FP,
    6. Shimada T
    (1996) 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem Pharmacol 51:313–319.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Combined Three-Dimensional Quantitative Structure-Activity Relationship Analysis of Cytochrome P450 2B6 Substrates and Protein Homology Modeling

Qinmi Wang and James R. Halpert
Drug Metabolism and Disposition January 1, 2002, 30 (1) 86-95; DOI: https://doi.org/10.1124/dmd.30.1.86
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement